The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
Identifying independent risk factors associated with severe plaque psoriasis is essential for the development of effective treatment strategies and improving outcomes.1 A multicenter study retrospectively analyzed data from 2,109 patients with plaque psoriasis from 12 hospitals in China to develop a severity risk prediction model. The LASSO logistic regression was used for multivariable analysis to identify independent risk factors and develop a predictive nomogram for PASI ≥10. Results from this study were published in Scientific Reports by Wang et al.1 |
Key learnings |
The Nomogram-10 prediction model incorporates 10 key risk factors associated with severe plaque psoriasis, including DELPHI consensus dichotomy, DLQI, BSA, age, sex, weight, career, scalp involvement, facial involvement, and arthropathy. |
In internal validation, the C-index was 0.863 (95% CI, 0.848–0.879), which was affirmed by bootstrap = 1,000 validation (C-index, 0.860; 95% CI, 0.836–0.885). |
The model was also validated using two external cohorts (n = 198 and n = 193), with a C-index of 0.910 (95% CI, 0.868–0.953) and 0.951 (95% CI, 0.924–0.977) in Cohort 1 and Cohort 2, respectively, indicating good discrimination. |
The Nomogram-10 model developed in this study offers an efficient and easily applicable predictive model to assess the risk of moderate-to-severe plaque psoriasis and can be used to develop personalized treatment strategies based on individual patients' risk. |
Abbreviations: BSA, body surface area; C-index, concordance index; CI, confidence interval; DLQI, Dermatology Life Quality Index; LASSO, least absolute shrinkage and selection operator; PASI, Psoriasis Area and Severity Index.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content